Cargando…

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries

INTRODUCTION: Reductions in HIV acquisition have slowed, and the global community is significantly off track from global goals. Oral pre‐exposure prophylaxis (PrEP) alone cannot address the diverse needs of the millions of people at risk of HIV acquisition. Long‐acting injectable cabotegravir (CAB‐L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenkins, Sarah Y., Resar, Danielle, Panos, Zachary, Staple, Alan, Watkins, Melynda, Ripin, David, Amole, Carolyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338995/ https://www.ncbi.nlm.nih.gov/pubmed/37439082 http://dx.doi.org/10.1002/jia2.26101

Ejemplares similares

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)

Cabotegravir
Publicado: (2022)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
por: Patel, Parul, et al.
Publicado: (2020)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
por: Grinsztejn, Beatriz, et al.
Publicado: (2023)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
por: Pepperrell, Toby, et al.
Publicado: (2022)

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
por: Letendre, Scott L, et al.
Publicado: (2020)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Injectable Long-Acting Cabotegravir–Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
por: Pinto, Rogério M., et al.
Publicado: (2023)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
por: Collins, Lauren F, et al.
Publicado: (2022)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
por: Rizzardini, Giuliano, et al.
Publicado: (2020)

887. Implementation of Long-acting Injectable Cabotegravir/Rilpivirine for HIV-1 Treatment at a Ryan White-funded Clinic in the U.S. South
por: Collins, Lauren F, et al.
Publicado: (2021)

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects
por: Han, Kelong, et al.
Publicado: (2022)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
por: Pintado, Claire, et al.
Publicado: (2020)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?
por: Sahloff, Eric G, et al.
Publicado: (2022)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
por: Teichner, Paula, et al.
Publicado: (2019)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial
por: Williams, Jamila K, et al.
Publicado: (2023)

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)
por: Rael, Christine Tagliaferri, et al.
Publicado: (2021)

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies
por: Teichner, Paula, et al.
Publicado: (2020)

The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
por: Smith, Jennifer A, et al.
Publicado: (2020)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Income assistance, marriage, and child poverty: An assessment of the Family Security Act()
por: Ortigueira, Salvador, et al.
Publicado: (2022)

1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results
por: Chounta, Vasiliki, et al.
Publicado: (2020)

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
por: Murray, Miranda, et al.
Publicado: (2020)

Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers
por: Jucker, Beat M., et al.
Publicado: (2021)

Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
por: Young, Isabella C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fh6hv8tlncfctkd2s4m6d8rslq